Rituximab in severe skin diseases: target, disease, and dose

New clinical indications for rituximab seem to appear every day. This review will trace the use of this monoclonal antibody from lymphoid malignancy, to classic autoimmune disease, and specifically severe autoimmune skin diseases. The history leading to different dosing schema with associated pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Daniel D, Ohanian, Maro, Cable, Christian T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262375/
https://www.ncbi.nlm.nih.gov/pubmed/22291497
_version_ 1782221716609564672
author Bennett, Daniel D
Ohanian, Maro
Cable, Christian T
author_facet Bennett, Daniel D
Ohanian, Maro
Cable, Christian T
author_sort Bennett, Daniel D
collection PubMed
description New clinical indications for rituximab seem to appear every day. This review will trace the use of this monoclonal antibody from lymphoid malignancy, to classic autoimmune disease, and specifically severe autoimmune skin diseases. The history leading to different dosing schema with associated pharmacokinetic data will be discussed. A case of livedoid vasculopathy (atrophie blanche) responding to rituximab will illustrate how the response to therapy can help to elucidate previously obscure pathophysiology.
format Online
Article
Text
id pubmed-3262375
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32623752012-01-30 Rituximab in severe skin diseases: target, disease, and dose Bennett, Daniel D Ohanian, Maro Cable, Christian T Clin Pharmacol Review New clinical indications for rituximab seem to appear every day. This review will trace the use of this monoclonal antibody from lymphoid malignancy, to classic autoimmune disease, and specifically severe autoimmune skin diseases. The history leading to different dosing schema with associated pharmacokinetic data will be discussed. A case of livedoid vasculopathy (atrophie blanche) responding to rituximab will illustrate how the response to therapy can help to elucidate previously obscure pathophysiology. Dove Medical Press 2010-07-07 /pmc/articles/PMC3262375/ /pubmed/22291497 Text en © 2010 Bennett et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Bennett, Daniel D
Ohanian, Maro
Cable, Christian T
Rituximab in severe skin diseases: target, disease, and dose
title Rituximab in severe skin diseases: target, disease, and dose
title_full Rituximab in severe skin diseases: target, disease, and dose
title_fullStr Rituximab in severe skin diseases: target, disease, and dose
title_full_unstemmed Rituximab in severe skin diseases: target, disease, and dose
title_short Rituximab in severe skin diseases: target, disease, and dose
title_sort rituximab in severe skin diseases: target, disease, and dose
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262375/
https://www.ncbi.nlm.nih.gov/pubmed/22291497
work_keys_str_mv AT bennettdanield rituximabinsevereskindiseasestargetdiseaseanddose
AT ohanianmaro rituximabinsevereskindiseasestargetdiseaseanddose
AT cablechristiant rituximabinsevereskindiseasestargetdiseaseanddose

Ejemplares similares